CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors

Christopher Moertela Department of Pediatrics, University of Minnesota, Minneapolis, MN, USACorrespondence[email protected]
View further author information

Francisco Martinez-Puertaa Department of Pediatrics, University of Minnesota, Minneapolis, MN, USAView further author information

Grace G. Elizabeth Pluharb Department of Veterinary Clinical Sciences, University of Minnesota Twin Cities, Minneapolis, MN, USAView further author information

Maria Graciela Castroc Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, USA

https://orcid.org/0000-0003-2237-2756 View further author information

Michael Olina Department of Pediatrics, University of Minnesota, Minneapolis, MN, USAView further author information

Click to increase image sizeClick to decrease image size

Declaration of interest

M Olin and C Moertel are officers in OX2 Therapeutics, a spinoff company of the University of Minnesota studying the CD200 checkpoint and possible therapeutic interventions based on exploitation of the CD200 pathway. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

No funding was received for this work.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors

Information for

Open access

Opportunities

Help and information

CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors

Declaration of interest

Reviewer disclosures

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature